Cargando…

Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-x(L) strategies through Mcl-1 down-regulation

Ovarian carcinoma is the leading cause of death from gynecologic cancer in the developed world and is characterized by acquired chemoresistance leading to an overall 5-year survival rate of about 30 %. We previously showed that Bcl-x(L) and Mcl-1 cooperatively protect platinum-resistant ovarian canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonnefond, Marie-Laure, Lambert, Bernard, Giffard, Florence, Abeilard, Edwige, Brotin, Emilie, Louis, Marie-Hélène, Gueye, Mor Sény, Gauduchon, Pascal, Poulain, Laurent, N’Diaye, Monique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348506/ https://www.ncbi.nlm.nih.gov/pubmed/25627260 http://dx.doi.org/10.1007/s10495-015-1095-3

Ejemplares similares

Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-Bclx(L) strategies through Mcl-1 down-regulation
por: Bonnefond, Marie-Laure, et al.
Publicado: (2018)

Sensitization of ovarian carcinoma cells to Bcl-x(L)-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family
por: Tomasina, Julie, et al.
Publicado: (2013)

Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-x(L) inhibitors on human ovarian carcinoma cells
por: Lincet, Hubert, et al.
Publicado: (2013)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-X(L) and EGFR leading to BIM activation
por: Denoyelle, C, et al.
Publicado: (2014)

The lncRNA ‘UCA1’ modulates the response to chemotherapy of ovarian cancer through direct binding to miR‐27a‐5p and control of UBE2N levels
por: Wambecke, Anaïs, et al.
Publicado: (2021)

An overview of long non-coding RNAs in ovarian cancers
por: Meryet-Figuière, Matthieu, et al.
Publicado: (2016)

Network-Based Integration of Multi-Omics Data Identifies the Determinants of miR-491-5p Effects
por: Meryet-Figuiere, Matthieu, et al.
Publicado: (2021)

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma
por: Thorel, Lucie, et al.
Publicado: (2023)

Drug Repositioning of the α(1)-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug?
por: Florent, Romane, et al.
Publicado: (2020)

MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells
por: Veys, Clément, et al.
Publicado: (2023)

Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route
por: Meryet-Figuière, Matthieu, et al.
Publicado: (2017)

MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells
por: Ashofteh, Nooshin, et al.
Publicado: (2021)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma
por: Mukherjee, Nabanita, et al.
Publicado: (2020)

Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
por: Robinson, Edward J., et al.
Publicado: (2018)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
por: Mena, Salvador, et al.
Publicado: (2012)

The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance
por: Fitzgerald, Marie-Claire, et al.
Publicado: (2023)

Selective Affimers Recognise the BCL‐2 Family Proteins BCL‐x(L) and MCL‐1 through Noncanonical Structural Motifs
por: Miles, Jennifer A., et al.
Publicado: (2020)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)

The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2
Publicado: (1995)

Cyclic Marinopyrrole Derivatives as Disruptors of Mcl-1 and Bcl-x(L) Binding to Bim
por: Cheng, Chunwei, et al.
Publicado: (2014)

Combined reduction in the expression of MCL-1 and BCL-2 reduces organismal size in mice
por: Ke, Francine, et al.
Publicado: (2020)

Correction to: Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
por: Robinson, Edward J., et al.
Publicado: (2022)

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression
por: Yasuda, Yuto, et al.
Publicado: (2020)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines
por: Abdul Rahman, Siti Fairus, et al.
Publicado: (2020)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2
por: Basu, Alakananda, et al.
Publicado: (2017)

Computational design of an apoptogenic protein that binds BCL-xL and MCL-1 simultaneously and potently
por: Kim, Seonghoon, et al.
Publicado: (2022)

Simultaneous Inhibition of Mcl-1 and Bcl-2 Induces Synergistic Cell Death in Hepatocellular Carcinoma
por: Michalski, Marlen, et al.
Publicado: (2023)

C-type lectin receptors Mcl and Mincle control development of multiple sclerosis–like neuroinflammation
por: N’diaye, Marie, et al.
Publicado: (2020)

Comments by Microbiologists for Interpreting Antimicrobial Susceptibility Testing and Improving the Appropriateness of Antibiotic Therapy in Community-Acquired Urinary Tract Infections: A Randomized Double-Blind Digital Case-Vignette Controlled Superiority Trial
por: Piet, Emilie, et al.
Publicado: (2023)

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021)

Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1
por: Ow, Thomas J., et al.
Publicado: (2019)

Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
por: Bourafai-Aziez, Asma, et al.
Publicado: (2021)

Mcl-1 promotes survival of thymocytes by inhibition of Bak in a pathway separate from Bcl-2
por: Dunkle, Alexis, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_s99e076m2bbmi4tmg1muj1a9pu